
Product Description
| Product Name | Anti-EGFRvIII Monoclonal Antibody, Recombinant |
| Catalog # | EG-369 |
| Size | 100 µg |
| Key Features |
|
| Clone Number | R6 |
| Immunogen | Proprietary peptide |
| Target | Human EGFRvIII mutant |
| Species Cross-Reactivity | Human |
| Applications | Flow Cytometry, Immunoprecipitation (IP), ELISA, Western Blot |
| Recommended Working Concentrations |
|
| Background |
Epidermal growth factor receptor variant III (EGFRvIII) is the most common EGFR mutation, present in up to 30% of high-grade gliomas, particularly glioblastoma multiforme (GBM). EGFRvIII is a cancer-specific deletion mutant, restrictively expressed in glioblastoma and some lung cancers, and is not detected in normal tissues. EGFRvIII plays a critical role in tumorigenesis, disease progression, and metastasis, and is recognized as a cancer driver mutation in glioblastoma. Its expression is associated with poor prognosis, making EGFRvIII an ideal target for immunotherapy. References: 1. Yang J., et al. Cancer Lett. 2017;403:224-30. 2. Jungbluth A.A., et al. PNAS. 2003;100:639-644. |
| Quality Control |
Fig. A: Flow cytometry assay demonstrating cell binding specificity. U87 cells (EGFRvIII negative), U87 (EGFR++), and U87 (EGFRvIII++) cells were stained with 5 µg antibody in 1 mL PBS containing 5% BSA. Binding was detected with a Cy5-conjugated goat anti-rabbit antibody. Shaded area: isotype control; red line: EGFRvIII antibody staining. |
| Concentration | As indicated on the vial label |
| Formulation | 80% PBS, pH 7.4; 20% glycerol; 5% trehalose; 0.04% sodium azide (preservative) |
| Shipping | Shipped on blue ice |
| Storage |
Store at -20 to -70 °C (long-term), or at 4 °C for up to one week. For frequent use, aliquot to avoid repeated freeze-thaw cycles. |
Related Products